Oncology pipeline: research, clinical trials and treatments
We are committed to transforming the lives of people with cancer through innovative therapies. Our robust pipeline spans cancer cell–directed and immuno-oncology investigational therapies. Through global collaboration, we are tackling some of the most challenging, but potentially most impactful, areas of cancer research.
Latest development phase
As of May 2026
Cancer cell–directed
HER2 TKI
Phase I
Active, not recruiting
Solid tumors (Phase Ia) and NSCLC (Phase Ib)
(Recruiting for cohorts 7 and 8 only)
Phase II*
Recruiting
NSCLC, solid tumors, breast cancer, gastric adenocarcinoma, GEJ adenocarcinoma and esophageal adenocarcinoma
± combination
T-cell engagers
DLL3/CD3 T-cell engager
B7-H6/CD3 T-cell engager
Phase I
Recruiting
Solid tumors, colorectal carcinoma, gastric carcinoma and PDAC
± combination
Oncolytic viruses
VSV-GP oncolytic virus
Immuno-modulators
CD137xFAP bsAb
Phase I
Active, not recruiting (Phase Ib)
Solid tumors and HNSCC
± combination
SIRPα antagonist
Phase I
Recruiting
Solid tumors and HNSCC
(Recruiting for Phase Ib)
± combination
STING agonist
Immunological fusion protein
PD-1 inhibitor
*Beamion™ BCGC-1 is a Phase I/II trial; †1438-0002 is a Phase I/II trial.
Download a summary of ongoing clinical trials
-
Heymach JV, et al. J Clin Oncol 2025;43(11):1337–1347.
-
Heymach JV, et al. N Engl J Med 2025;392(23):2321–2333.
-
ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/study/NCT04886804 (Accessed: May 2026).
-
ClinicalTrials.gov. NCT06151574. https://clinicaltrials.gov/study/NCT06151574 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT06581432. https://clinicaltrials.gov/study/NCT06581432 (Accessed: April 2026).
-
Schram AM, et al. J Clin Oncol 2025;43(16_suppl). Abstract TPS3187.
-
ClinicalTrials.gov. NCT06324357. https://clinicaltrials.gov/study/NCT06324357 (Accessed: April 2026).
-
Nakayama I, et al. J Clin Oncol 2025;43(4_suppl). Abstract TPS509.
-
Hurvitz SA, et al. ESMO Open 2025;10(S4). Abstract 409TiP.
-
ClinicalTrials.gov. NCT07486817. https://clinicaltrials.gov/study/NCT07486817 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT07195695. https://clinicaltrials.gov/study/NCT07195695 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/study/NCT04429087 (Accessed: April 2026).
-
Wermke M, et al. J Clin Oncol 2025;43(27):3021–3031.
-
ClinicalTrials.gov. NCT05879978. https://clinicaltrials.gov/study/NCT05879978 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/study/NCT05882058 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT06132113. https://clinicaltrials.gov/study/NCT06132113 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT06077500. https://clinicaltrials.gov/study/NCT06077500 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT05990738. https://clinicaltrials.gov/study/NCT05990738 (Accessed: April 2026).
-
Wermke M, et al. ASCO 2025. Poster 8094.
-
ClinicalTrials.gov. NCT07544654. https://clinicaltrials.gov/study/NCT07544654 (Accessed: May 2026).
-
ClinicalTrials.gov. NCT07472517. https://clinicaltrials.gov/study/NCT07472517 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT06091930. https://clinicaltrials.gov/study/NCT06091930 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT06882746. https://clinicaltrials.gov/study/NCT06882746 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT05155332. https://clinicaltrials.gov/study/NCT05155332 (Accessed: April 2026).
-
Shroff RT, et al. Cancer Res 2025;85(8_Supplement_2). Abstract CT110.
-
ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/study/NCT04958239 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/study/NCT05327946 (Accessed: April 2026).
-
Wang JS, et al. J Clin Oncol 2025;43(16_suppl). Abstract 2515.
-
ClinicalTrials.gov. NCT06806852. https://clinicaltrials.gov/study/NCT06806852 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856 (Accessed: April 2026).
-
ClinicalTrials.gov. NCT07224425. https://clinicaltrials.gov/study/NCT07224425 (Accessed: April 2026).
bsAb, bispecific antibody; CD, cluster of differentiation; DLL3, delta-like ligand 3; epNEC, extrapulmonary neuroendocrine carcinoma; FAP, fibroblast activation protein; GEJ, gastroesophageal junction; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; NEC, neuroendocrine carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; PDAC, pancreatic ductal adenocarcinoma; SCLC, small cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, small molecule agonist of the stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.